(Total Views: 140)
Posted On: 10/20/2020 8:55:40 AM
Post# of 17845
$NBIO SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"
is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB" successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies.
Alison Patteson, an assistant professor of physics, is leading a team researching the connections between the COVID-19 virus and pritumumab, a naturally occurring antibody, which has been used to inhibit cancer and tumor growth. Patteson tested whether the antibody blocks SARS-CoV-2, the virus responsible for COVID-19, from entering cells. "Evidence has been found that the antibody does block the uptake to viral particles," Patteson said. The entire Syracuse Press release can be seen at: http://dailyorange.com/2020/10/professor-rese...-covid-19/
is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB" successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies. Alison Patteson, an assistant professor of physics, is leading a team researching the connections between the COVID-19 virus and pritumumab, a naturally occurring antibody, which has been used to inhibit cancer and tumor growth. Patteson tested whether the antibody blocks SARS-CoV-2, the virus responsible for COVID-19, from entering cells. "Evidence has been found that the antibody does block the uptake to viral particles," Patteson said. The entire Syracuse Press release can be seen at: http://dailyorange.com/2020/10/professor-rese...-covid-19/
(0)
(0)Scroll down for more posts ▼
